Two randomized controlled trials of ceftazidime alone versus ceftazidime in combination with trimethoprim-sulfamethoxazole for the treatment of severe melioidosis

Clinical Infectious Diseases

Volumn 41, Issue 8, 2005, Pages 1105-1113

  Chierakul, Wirongrong ^a,b   Anunnatsiri, Siriluck ^c   Short, Jennifer M ^b,e   Maharjan, Bina ^b   Mootsikapun, Piroon ^c   Simpson, Andrew J H ^b,e   Limmathurotsakul, Direk ^b   Cheng, Allen C ^b   Stepniewska, Kasia ^b,e   Newton, Paul N ^b,e   Chaowagul, Wipada ^d   White, Nicholas J ^b,e   Peacock, Sharon J ^b,e   Day, Nicholas P ^a,b,e   Chetchotisakd, Ploenchan ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^c KHON KAEN UNIVERSITY   (Thailand)

^d Sappasitthiprasong Hospital   (Thailand)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME; COTRIMOXAZOLE;

ARTICLE; BACTEREMIA; BURKHOLDERIA PSEUDOMALLEI; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG FATALITY; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MELIOIDOSIS; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; THAILAND; TREATMENT FAILURE;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BURKHOLDERIA PSEUDOMALLEI; CEFTAZIDIME; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MELIOIDOSIS; MIDDLE AGED; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 26444505890     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/444456     Document Type: Article

References (11)

1. Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1989; 159:890-9.
2. Currie BJ, Fisher DA, Howard DM, et al. Endemic melioidosis in tropical northern Australia: a 10-year prospective study and review of the literature. Clin Infect Dis 2000; 31:981-6.
3. White NJ, Dance DA, Chaowagul W, Wattanagoon Y, Wuthiekanun V, Pitakwatchara N. Halving of mortality of severe melioidosis by ceftazidime [see comments]. Lancet 1989; 2:697-701.
4. Sookpranee M, Boonma P, Susaengrat W, Bhuripanyo K, Punyagupta S. Multicenter prospective randomized trial comparing ceftazidime plus co-trimoxazole with chloramphenicol plus doxycycline and co-trimoxazole for treatment of severe melioidosis. Antimicrob Agents Chemother 1992; 36:158-62.
5. Dance DA, Wuthiekanun V, Chaowagul W, White NJ. Interactions in vitro between agents used to treat melioidosis. J Antimicrob Chemother 1989; 24:311-6.
6. Walsh AL, Wuthiekanun V. The laboratory diagnosis of melioidosis. Br J Biomed Sci 1996; 53:249-53.
7. Piliouras P, Ulett GC, Ashhurst-Smith C, Hirst RG, Norton RE. A comparison of antibiotic susceptibility testing methods for cotrimoxazole with Burkholderia pseudomallei. Int J Antimicrob Agents 2002; 19:427-9.
8. NCCLS. Performance standards for antimicrobial susceptibility testing; fourteenth informational supplement. NCCLS document M100-S14. Wayne, PA: NCCLS, 2004.
9. Suputtamongkol Y, Rajchanuwong A, Chaowagul W, et al. Ceftazidime vs. amoxicillin/clavulanate in the treatment of severe melioidosis. Clin Infect Dis 1994; 19:846-53.
10. Simpson AJ, Suputtamongkol Y, Smith MD, et al. Comparison of imipenem and ceftazidime as therapy for severe melioidosis. Clin Infect Dis 1999; 29:381-7.
11. Chetchotisakd P, Porramatikul S, Mootsikapun P, Anunnatsiri S, Thinkhamrop B. Randomized, double-blind, controlled study of cefoperazone-sulbactam plus cotrimoxazole versus ceftazidime plus cotrimoxazole for the treatment of severe melioidosis. Clin Infect Dis 2001; 33:29-34.